chromosome 9 putative open reading frame 163Genealiases: []
Q-omics provides the consensus-scored C9orf163 profile across patient tissues and cancer cell-line models. C9orf163 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C9orf163 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, C9orf163 RNA expression shows 17,952 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where C9orf163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf163 survival associations across molecular data types. C9orf163 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf163 RNA expression–survival associations across cancer types. High C9orf163 expression shows unfavorable associations in KIRC, ACC, COAD and LGG, but favorable associations in THYM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C9orf163 RNA expression.
This table summarizes C9orf163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf163 shows higher tumor expression in COAD, BLCA, LIHC, HNSC, BRCA and LUSC. The COAD box plot shows higher C9orf163 RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with C9orf163 in patient tissues and cancer cell lines. In patient samples, C9orf163 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf163 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
